MangoceuticalsMGRX -1.46%26 PB Ratio is 0.46 as of Jul. 13, 2026, which is 51% below its 10-year median of 0.94. GuruFocus rates MGRX with a GF Score™ of 26/100 and a GF Value™ of $0.32 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Mangoceuticals ranks better than 94.23% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), Mangoceuticals's share price is $0.365. Mangoceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was $0.79. Hence, Mangoceuticals's PB Ratio of today is 0.46.
The historical rank and industry rank for Mangoceuticals's PB Ratio or its related term are showing as below:
MGRX'
s PB Ratio Range Over the Past 10 Years
Min: 0.17 Med: 0.94 Max: 61.9
Current: 0.46
During the past 5 years, Mangoceuticals's highest PB Ratio was 61.90. The lowest was 0.17. And the median was 0.94.
MGRX's PB Ratio is ranked better than 94.23% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 2.03
vs MGRX: 0.46
During the past 12 months, Mangoceuticals's average Book Value Per Share Growth Rate was -72.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.80% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Mangoceuticals was 16.80% per year. The lowest was 16.80% per year. And the median was 16.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mangoceuticals PB Ratio Related Terms
Mangoceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for Mangoceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Mangoceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangoceuticals PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mangoceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Mangoceuticals's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mangoceuticals (MGRX) has a PB Ratio of 0.46 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mangoceuticals and its competitors. This is 51% below median its historical median of 0.94. Over the past decade, Mangoceuticals' PB Ratio has ranged from 0.17 to 61.90. According to the industry distribution chart, Mangoceuticals ranks #35 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 5.8%.
Is Mangoceuticals' PB Ratio too high?
Mangoceuticals' current PB Ratio of 0.46 is 51% below median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 61.90. The Healthcare Providers & Services industry median PB Ratio is 2.03. Mangoceuticals' value of 0.46 is 77.3% below this industry median. Based on the distribution chart, Mangoceuticals ranks #35 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mangoceuticals has a GF Score™ of 26/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' PB Ratio compare to WLSS and ACON?
According to the Healthcare Providers & Services industry distribution chart, Mangoceuticals ranks #35 out of 607 companies for PB Ratio. This places Mangoceuticals in the top 6% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.03. Mangoceuticals' value of 0.46 is 77.3% below this benchmark. Historically, Mangoceuticals' own PB Ratio has ranged from 0.17 to 61.90 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 2.03, Mangoceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 2.03, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangoceuticals's current PB Ratio of 0.46 is 77.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mangoceuticals and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangoceuticals's current PB Ratio is 0.46, which is 51% below median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.37 — trading 14.1% above its estimated fair value. The current PB Ratio is 0.46, which is 51% below median its 10-year median of 0.94 and 77.3% below the Healthcare Providers & Services industry median of 2.03. Mangoceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current PB Ratio is 0.46 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangoceuticals (MGRX) Overvalued in 2026?
Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued.
The current stock price of $0.37 is trading 14.1% above its estimated GF Value™ of $0.32.
GuruFocus considers Mangoceuticals to be Modestly Overvalued.
Key valuation signals for MGRX:
PB Ratio: 0.46 (51% below median its 10-year median of 0.94)
GF Value™: $0.32 vs. price of $0.37 (14.1% above fair value)
Industry Position: 77.3% below the Healthcare Providers & Services median (#35 of 607)
No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
26GF Score
Get the complete analysis for MGRX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGRX has been successfully added to your 
